This morning, Vertex Pharmaceuticals announced the results from the Phase 3 clinical trials of ivacaftor (Kalydeco™) and lumacaftor (VX-809) in people with two copies of the F508del mutation.
Site Search
A comprehensive, updated resource to assist the cystic fibrosis community with infection prevention and control practices is now available online. “Infection Prevention and Control Guideline for Cystic Fibrosis: 2013 Update” will also be published in the August print edition of Infection Control & Hospital Epidemiology, the official journal of the Society for Healthcare Epidemiology of America.
Since our founding in 1955, we have worked alongside the cystic fibrosis community to effectively transform a genetic disease in a single generation — making CF one of the most amazing stories in medicine today. Read about the milestones we've achieved in pursuit of a cure for cystic fibrosis.
On Mar. 11, the Cystic Fibrosis Foundation presented the Alex, Jena and Dream Big Awards to leaders in the CF community for their dedication to the Foundation's mission of finding a cure.
As a mother of three sons with cystic fibrosis, Mary along with her husband, Harry, was determined to do all she could to find a cure.
As part of its Building Trust Video series, the Better Business Bureau's (BBB) Wise Giving Alliance is featuring an interview with Preston W. Campbell, III, M.D., president and CEO of the Cystic Fibrosis Foundation.
The Cystic Fibrosis Foundation invited more than 100 scientists to its research conference in Savannah, Ga., last month to discuss recent advancements in gene therapy, gene editing and stem-cell biology and how these new technologies could be applied to finding a one-time cure for cystic fibrosis.
Garry Shandling leaves a legacy gift to the Foundation in honor of his late brother, who had cystic fibrosis.